Published in J Med Chem on July 17, 2003
DNA topoisomerase I inhibitors: chemistry, biology, and interfacial inhibition. Chem Rev (2009) 2.65
The indenoisoquinoline noncamptothecin topoisomerase I inhibitors: update and perspectives. Mol Cancer Ther (2009) 1.64
A novel norindenoisoquinoline structure reveals a common interfacial inhibitor paradigm for ternary trapping of the topoisomerase I-DNA covalent complex. Mol Cancer Ther (2006) 1.36
Synthesis and evaluation of indenoisoquinoline topoisomerase I inhibitors substituted with nitrogen heterocycles. J Med Chem (2006) 1.29
Total synthesis and biological evaluation of 22-hydroxyacuminatine. J Med Chem (2006) 1.18
A systematic study of nitrated indenoisoquinolines reveals a potent topoisomerase I inhibitor. J Med Chem (2006) 1.07
Design, synthesis, and biological evaluation of 14-substituted aromathecins as topoisomerase I inhibitors. J Med Chem (2008) 1.05
Investigation of the lactam side chain length necessary for optimal indenoisoquinoline topoisomerase I inhibition and cytotoxicity in human cancer cell cultures. J Med Chem (2007) 0.99
The structure-activity relationships of A-ring-substituted aromathecin topoisomerase I inhibitors strongly support a camptothecin-like binding mode. Bioorg Med Chem (2010) 0.87
Structure-based design, synthesis, and biological studies of new anticancer norindenoisoquinoline topoisomerase I inhibitors. J Med Chem (2010) 0.85
Design, synthesis, and biological evaluation of O-2-modified indenoisoquinolines as dual topoisomerase I-tyrosyl-DNA phosphodiesterase I inhibitors. J Med Chem (2014) 0.85
Gold(III) macrocycles: nucleotide-specific unconventional catalytic inhibitors of human topoisomerase I. J Am Chem Soc (2014) 0.83
A Facile method to transform trans-4-carboxy-3,4-dihydro-3-phenyl- 1(2H)-isoquinolones to indeno[1,2-c]isoquinolines. J Org Chem (2005) 0.81
Synthesis and biological evaluation of 14-(aminoalkyl-aminomethyl)aromathecins as topoisomerase I inhibitors: investigating the hypothesis of shared structure-activity relationships. Bioorg Med Chem (2009) 0.79
Sequential Cu(I)/Pd(0)-catalyzed multicomponent coupling and annulation protocol for the synthesis of indenoisoquinolines. Org Lett (2009) 0.78
Quantitative structure-activity relationship studies on indenoisoquinoline topoisomerase I inhibitors as anticancer agents in human renal cell carcinoma cell line SN12C. Int J Mol Sci (2012) 0.76
Design, Synthesis, and Biological Evaluation of Potential Prodrugs Related to the Experimental Anticancer Agent Indotecan (LMP400). J Med Chem (2016) 0.75
GammaH2AX and cancer. Nat Rev Cancer (2008) 9.77
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. Cancer Res (2012) 3.74
The mechanism of topoisomerase I poisoning by a camptothecin analog. Proc Natl Acad Sci U S A (2002) 3.71
Biological and structural characterization of a host-adapting amino acid in influenza virus. PLoS Pathog (2010) 3.65
Apoptotic susceptibility of cancer cells selected for camptothecin resistance: gene expression profiling, functional analysis, and molecular interaction mapping. Cancer Res (2003) 3.52
Phosphorylation of histone H2AX and activation of Mre11, Rad50, and Nbs1 in response to replication-dependent DNA double-strand breaks induced by mammalian DNA topoisomerase I cleavage complexes. J Biol Chem (2003) 3.45
The complexity of phosphorylated H2AX foci formation and DNA repair assembly at DNA double-strand breaks. Cell Cycle (2010) 2.84
Molecular interaction maps of bioregulatory networks: a general rubric for systems biology. Mol Biol Cell (2005) 2.82
Mutagenic processing of ribonucleotides in DNA by yeast topoisomerase I. Science (2011) 2.73
Topoisomerase I suppresses genomic instability by preventing interference between replication and transcription. Nat Cell Biol (2009) 2.60
CellMiner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set. Cancer Res (2012) 2.57
DNA fingerprinting of the NCI-60 cell line panel. Mol Cancer Ther (2009) 2.53
Repair of and checkpoint response to topoisomerase I-mediated DNA damage. Mutat Res (2003) 2.50
Cleaving the oxidative repair protein Ape1 enhances cell death mediated by granzyme A. Nat Immunol (2003) 2.48
The intra-S-phase checkpoint affects both DNA replication initiation and elongation: single-cell and -DNA fiber analyses. Mol Cell Biol (2007) 2.41
Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res (2003) 2.40
Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene (2004) 2.36
The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology. Cancer Res (2013) 2.27
Novel indenoisoquinolines NSC 725776 and NSC 724998 produce persistent topoisomerase I cleavage complexes and overcome multidrug resistance. Cancer Res (2007) 2.26
Histone gammaH2AX and poly(ADP-ribose) as clinical pharmacodynamic biomarkers. Clin Cancer Res (2010) 2.12
Structures of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex. J Med Chem (2005) 2.12
Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res (2002) 2.09
Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas. Cancer Res (2011) 2.08
mRNA and microRNA expression profiles of the NCI-60 integrated with drug activities. Mol Cancer Ther (2010) 2.00
Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications. Cancer Res (2004) 1.96
Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis. Nat Chem Biol (2010) 1.94
Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety. Nat Biotechnol (2009) 1.91
Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572). Mol Pharmacol (2011) 1.87
Replication fork velocities at adjacent replication origins are coordinately modified during DNA replication in human cells. Mol Biol Cell (2007) 1.85
Evaluation of current methods used to analyze the expression profiles of ATP-binding cassette transporters yields an improved drug-discovery database. Mol Cancer Ther (2009) 1.83
Comparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutants. Biochemistry (2008) 1.82
Dual targeting of EWS-FLI1 activity and the associated DNA damage response with trabectedin and SN38 synergistically inhibits Ewing sarcoma cell growth. Clin Cancer Res (2013) 1.80
Synthesis and anti-HIV activity of new metabolically stable alkenyldiarylmethane non-nucleoside reverse transcriptase inhibitors incorporating N-methoxy imidoyl halide and 1,2,4-oxadiazole systems. J Med Chem (2007) 1.76
Poly(ADP-ribose) polymerase and XPF-ERCC1 participate in distinct pathways for the repair of topoisomerase I-induced DNA damage in mammalian cells. Nucleic Acids Res (2011) 1.76
Resistance to integrase inhibitors. Viruses (2010) 1.75
Association of XRCC1 and tyrosyl DNA phosphodiesterase (Tdp1) for the repair of topoisomerase I-mediated DNA lesions. DNA Repair (Amst) (2003) 1.70
Ataxia telangiectasia mutated activation by transcription- and topoisomerase I-induced DNA double-strand breaks. EMBO Rep (2009) 1.69
Collaborative action of Brca1 and CtIP in elimination of covalent modifications from double-strand breaks to facilitate subsequent break repair. PLoS Genet (2010) 1.66
The indenoisoquinoline noncamptothecin topoisomerase I inhibitors: update and perspectives. Mol Cancer Ther (2009) 1.64
DNA cleavage assay for the identification of topoisomerase I inhibitors. Nat Protoc (2008) 1.61
Poly(ADP-ribose) polymerase inhibition enhances p53-dependent and -independent DNA damage responses induced by DNA damaging agent. Cell Cycle (2011) 1.60
CellMiner: a relational database and query tool for the NCI-60 cancer cell lines. BMC Genomics (2009) 1.58
Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib. Mol Cancer Ther (2013) 1.55
Suppression of survivin phosphorylation on Thr34 by flavopiridol enhances tumor cell apoptosis. Cancer Res (2003) 1.54
Inhibition of histone deacetylase in cancer cells slows down replication forks, activates dormant origins, and induces DNA damage. Cancer Res (2010) 1.53
HIV-1 IN inhibitors: 2010 update and perspectives. Curr Top Med Chem (2009) 1.53
The plug-based nanovolume Microcapillary Protein Crystallization System (MPCS). Acta Crystallogr D Biol Crystallogr (2008) 1.52
Nonclassic functions of human topoisomerase I: genome-wide and pharmacologic analyses. Cancer Res (2007) 1.51
Bloom's syndrome helicase and Mus81 are required to induce transient double-strand DNA breaks in response to DNA replication stress. J Mol Biol (2007) 1.50
Endogenous gamma-H2AX-ATM-Chk2 checkpoint activation in Bloom's syndrome helicase deficient cells is related to DNA replication arrested forks. Mol Cancer Res (2007) 1.46
Mechanisms of camptothecin resistance by human topoisomerase I mutations. J Mol Biol (2004) 1.46
Active site in RrmJ, a heat shock-induced methyltransferase. J Biol Chem (2002) 1.45
Hereditary ataxia SCAN1 cells are defective for the repair of transcription-dependent topoisomerase I cleavage complexes. DNA Repair (Amst) (2006) 1.45
Genome-wide depletion of replication initiation events in highly transcribed regions. Genome Res (2011) 1.44
Genome-wide mRNA and microRNA profiling of the NCI 60 cell-line screen and comparison of FdUMP[10] with fluorouracil, floxuridine, and topoisomerase 1 poisons. Mol Cancer Ther (2010) 1.44
Gene composer: database software for protein construct design, codon engineering, and gene synthesis. BMC Biotechnol (2009) 1.43
Tyrosyl-DNA phosphodiesterase as a target for anticancer therapy. Anticancer Agents Med Chem (2008) 1.43
Selective synthesis and biological evaluation of sulfate-conjugated resveratrol metabolites. J Med Chem (2010) 1.41
Phosphorylation of BLM, dissociation from topoisomerase IIIalpha, and colocalization with gamma-H2AX after topoisomerase I-induced replication damage. Mol Cell Biol (2005) 1.40
Combined protein construct and synthetic gene engineering for heterologous protein expression and crystallization using Gene Composer. BMC Biotechnol (2009) 1.40
Death receptor-induced activation of the Chk2- and histone H2AX-associated DNA damage response pathways. Mol Cell Biol (2008) 1.39
Integration requires a specific interaction of the donor DNA terminal 5'-cytosine with glutamine 148 of the HIV-1 integrase flexible loop. J Biol Chem (2005) 1.38
Elvitegravir overcomes resistance to raltegravir induced by integrase mutation Y143. AIDS (2011) 1.38
Biochemical and pharmacological analyses of HIV-1 integrase flexible loop mutants resistant to raltegravir. Biochemistry (2010) 1.38
Ecteinascidin 743 interferes with the activity of EWS-FLI1 in Ewing sarcoma cells. Neoplasia (2011) 1.37
Topoisomerase I levels in the NCI-60 cancer cell line panel determined by validated ELISA and microarray analysis and correlation with indenoisoquinoline sensitivity. Mol Cancer Ther (2009) 1.37
Processing of nucleopeptides mimicking the topoisomerase I-DNA covalent complex by tyrosyl-DNA phosphodiesterase. Nucleic Acids Res (2002) 1.37
Rif1 provides a new DNA-binding interface for the Bloom syndrome complex to maintain normal replication. EMBO J (2010) 1.36
A novel norindenoisoquinoline structure reveals a common interfacial inhibitor paradigm for ternary trapping of the topoisomerase I-DNA covalent complex. Mol Cancer Ther (2006) 1.36
Synergistic effects of peloruside A and laulimalide with taxoid site drugs, but not with each other, on tubulin assembly. Mol Pharmacol (2006) 1.36
Defective Mre11-dependent activation of Chk2 by ataxia telangiectasia mutated in colorectal carcinoma cells in response to replication-dependent DNA double strand breaks. J Biol Chem (2006) 1.36
Mus81-mediated DNA cleavage resolves replication forks stalled by topoisomerase I-DNA complexes. J Cell Biol (2011) 1.36
Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents. Proc Natl Acad Sci U S A (2012) 1.35
ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecan-treated metastases. Int J Cancer (2004) 1.35
Chk1 inhibition after replicative stress activates a double strand break response mediated by ATM and DNA-dependent protein kinase. Cell Cycle (2010) 1.35
Development of a validated immunofluorescence assay for γH2AX as a pharmacodynamic marker of topoisomerase I inhibitor activity. Clin Cancer Res (2010) 1.35